Last reviewed · How we verify
Immulina
Immulina is a Small molecule drug developed by University of Mississippi Medical Center. It is currently in Phase 3 development. Also known as: Spirulina.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Immulina |
|---|---|
| Also known as | Spirulina |
| Sponsor | University of Mississippi Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection (PHASE3)
- Effects of Immulina TM Supplements With PASC Patients (PHASE3)
- Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM (Trademark) in Normal Humans (PHASE3)
- Effects of Immulina on Immune Measures (NA)
- Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immulina CI brief — competitive landscape report
- Immulina updates RSS · CI watch RSS
- University of Mississippi Medical Center portfolio CI
Frequently asked questions about Immulina
What is Immulina?
Who makes Immulina?
Is Immulina also known as anything else?
What development phase is Immulina in?
Related
- Manufacturer: University of Mississippi Medical Center — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Spirulina
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing